Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.

ABSTRACT: There is a rapidly expanding literature on the in vitro antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). However, this has not been accompanied by a comprehensive evaluation of the target plasma and lung concentrations of these drugs following approved dosing in humans. Accordingly, concentration 90% (EC₉₀ ) values recalculated from in vitro anti-SARS-CoV-2 activity data was expressed as a ratio to the achievable maximum plasma concentration (C_max ) at an approved dose in humans (C_max /EC₉₀ ratio). Only 14 of the 56 analyzed drugs achieved a C_max /EC₉₀ ratio above 1. A more in-depth assessment demonstrated that only nitazo

SUBMITTER: Arshad U 

PROVIDER: S-EPMC7280633 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature